Aclidinium bromide/formoterol fumarate as a treatment for COPD: an update

References

• Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease 2021, [cited 2020 Nov 25]. https://goldcopd.org/wp-content/uploads/2020/11/GOLD-REPORT-2021-v1.0-16Nov20_WMV.pdf
   Google Scholar
• Rogliani P, Calzetta L, Braido F, et al. LABA/LAMA fixed-dose combinations in patients with COPD: a systematic review. Int J Chron Obstruct Pulmon Dis. 2018;13:3115–3130.
   PubMed Web of Science ®Google Scholar
• Calzetta L, Matera MG, Cazzola M. Pharmacological mechanisms leading to synergy in fixed-dose dual bronchodilator therapy. Curr Opin Pharmacol. 2018;40:95–103.
   PubMed Web of Science ®Google Scholar
• Nici L, Mammen MJ, Charbek E, et al. Pharmacologic management of chronic obstructive pulmonary disease: an official American Thoracic Society Clinical Practice Guideline. Am J Respir Crit Care Med. 2020;201(9):e56–e69.
   PubMed Web of Science ®Google Scholar
• AstraZeneca PLC. Duaklir® Genuair™ summary of product characteristics, 2019, [cited 2020 May 29]. http://www.medicines.org.uk/emc/medicine/29652
   Google Scholar
• AstraZeneca PLC. Bevespi® Aerosphere® highlights of prescribing information, 2020, [cited 2020 Aug 12]. https://www.azpicentral.com/bevespi/bevespi.pdf
   Google Scholar
• Novartis Pharmaceuticals UK Ltd. Ultibro® Breezhaler® summary of product characteristics, 2020, [cited 2020 May 29]. http://www.medicines.org.uk/emc/medicine/29533
   Google Scholar
• GlaxoSmithKline PLC. Anoro® Ellipta® summary of product characteristics, 2019, [cited 2020 May 29]. https://www.medicines.org.uk/emc/medicine/28949/
   Google Scholar
• GlaxoSmithKline PLC. Anoro® Ellipta® highlights of prescribing information, 2020, [cited 2020 May 29]. https://www.gsksource.com/pharma/content/dam/GlaxoSmithKline/US/en/Prescribing_Information/Anoro_Ellipta/pdf/ANORO-ELLIPTA-PI-PIL-IFU.PDF
   Google Scholar
• Boehringer Ingelheim GmbH. Spiolto® Respimat® summary of product characteristics, 2019, [cited 2020 May 29]. https://www.medicines.org.uk/emc/medicine/30495
   Google Scholar
• Boehringer Ingelheim GmbH. Stiolto™ Respimat® highlights of prescribing information, 2018, [cited 2020 May 29]. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/206756s009lbl.pdf
   Google Scholar
• AstraZeneca PLC. Duaklir® Genuair® highlights of prescribing information, 2019, [cited 2020 May 29]. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210595lbl.pdf
   Google Scholar
• Chrystyn H, Niederlaender C. The Genuair® inhaler: a novel, multidose dry powder inhaler. Int J Clin Pract. 2012;66(3):309–317.
   PubMed Web of Science ®Google Scholar
• Laube BL, Janssens HM, de Jongh FH, et al. What the pulmonary specialist should know about the new inhalation therapies. Eur Respir J. 2011;37(6):1308–1331.
   PubMed Web of Science ®Google Scholar
• Magnussen H, Watz H, Zimmermann I, et al. Peak inspiratory flow through the Genuair® inhaler in patients with moderate or severe COPD. Respir Med. 2009;103(12):1832–1837.
   PubMed Web of Science ®Google Scholar
• Singh D, Jones PW, Bateman ED, et al. Efficacy and safety of aclidinium bromide/formoterol fumarate fixed-dose combinations compared with individual components and placebo in patients with COPD (ACLIFORM-COPD): a multicentre, randomised study. BMC Pulm Med. 2014;14(1):178.
   PubMed Web of Science ®Google Scholar
• D’Urzo AD, Rennard SI, Kerwin EM, et al. Efficacy and safety of fixed-dose combinations of aclidinium bromide/formoterol fumarate: the 24-week, randomized, placebo-controlled AUGMENT COPD study. Respir Res. 2014;15(1):123.
   PubMed Web of Science ®Google Scholar
• Bateman ED, Chapman KR, Singh D, et al. Aclidinium bromide and formoterol fumarate as a fixed-dose combination in COPD: pooled analysis of symptoms and exacerbations from two six-month, multicentre, randomised studies (ACLIFORM and AUGMENT). Respir Res. 2015;16(1):92.
   PubMed Web of Science ®Google Scholar
• Miravitlles M, Chapman KR, Chuecos F, et al. The efficacy of aclidinium/formoterol on lung function and symptoms in patients with COPD categorized by symptom status: a pooled analysis. Int J Chron Obstruct Pulmon Dis. 2016;11:2041–2053.
   PubMed Web of Science ®Google Scholar
• Singh S, Loke YK, Enright PL, et al. Mortality associated with tiotropium mist inhaler in patients with chronic obstructive pulmonary disease: systematic review and meta-analysis of randomised controlled trials. BMJ. 2011;342(jun14 1):d3215.
   PubMed Web of Science ®Google Scholar
• Singh S, Loke YK, Furberg CD. Inhaled anticholinergics and risk of major adverse cardiovascular events in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. JAMA. 2008;300(12):1439–1450.
   PubMed Web of Science ®Google Scholar
• Tashkin DP, Celli B, Senn S, et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med. 2008;359(15):1543–1554.
   PubMed Web of Science ®Google Scholar
• Tashkin DP, Leimer I, Metzdorf N, et al. Cardiac safety of tiotropium in patients with cardiac events: a retrospective analysis of the UPLIFT® trial. Respir Res. 2015;16(1):65.
   PubMed Web of Science ®Google Scholar
• Wang M-T, Liou J-T, Lin CW, et al. Association of cardiovascular risk with inhaled long-acting bronchodilators in patients with chronic obstructive pulmonary disease: a nested case-control study. JAMA Intern Med. 2018;178(2):229–238.
   PubMed Web of Science ®Google Scholar
• Wise RA, Chapman KR, Scirica BM, et al. Effect of aclidinium bromide on major cardiovascular events and exacerbations in high-risk patients with chronic obstructive pulmonary disease: the ASCENT-COPD randomized clinical trial. JAMA. 2019;321(17):1693–1701.
   PubMed Web of Science ®Google Scholar
• Mann M, Meyer RJ. Drug development for asthma and COPD: a regulatory perspective. Respir Care. 2018;63(6):797–817.
   PubMed Web of Science ®Google Scholar
• Sethi S, Kerwin E, Watz H, et al. AMPLIFY: a randomized, phase III study evaluating the efficacy and safety of aclidinium/formoterol vs monocomponents and tiotropium in patients with moderate-to-very severe symptomatic COPD. Int J Chron Obstruct Pulmon Dis. 2019;14:667–682.
   PubMed Web of Science ®Google Scholar
• Singh D, D’Urzo AD, Donohue JF, et al. An evaluation of single and dual long-acting bronchodilator therapy as effective interventions in maintenance therapy-naïve patients with COPD. Int J Chron Obstruct Pulmon Dis. 2019;14:2835–2848.
   PubMed Web of Science ®Google Scholar
• Plate T, Friedrich FW, Beier J. Effectiveness and tolerability of LABA/LAMA fixed-dose combinations aclidinium/formoterol, glycopyrronium/indacaterol and umeclidinium/vilanterol in the treatment of COPD in daily practice – results of the non-interventional DETECT study. Int J Chron Obstruct Pulmon Dis. 2020;15:1335–1347.
   PubMed Web of Science ®Google Scholar
• Domnik NJ, James MD, Scheeren RE, et al. Deterioration of nighttime respiratory mechanics in COPD: impact of bronchodilator therapy. Chest. 2020;159(1):116–127.
   PubMed Web of Science ®Google Scholar
• D’Urzo AD, Singh D, Donohue JF, et al. Efficacy of aclidinium/formoterol 400/12 µg, analyzed by airflow obstruction severity, age, sex, and exacerbation history: pooled analysis of ACLIFORM and AUGMENT. Int J Chron Obstruct Pulmon Dis. 2019;14:479–491.
   PubMed Web of Science ®Google Scholar
• Price D, Small M, Milligan G, et al. Impact of night-time symptoms in COPD: a real-world study in five European countries. Int J Chron Obstruct Pulmon Dis. 2013;8:595–603.
   PubMed Web of Science ®Google Scholar
• Watz H, Troosters T, Beeh KM, et al. ACTIVATE: the effect of aclidinium/formoterol on hyperinflation, exercise capacity, and physical activity in patients with COPD. Int J Chron Obstruct Pulmon Dis. 2017;12:2545–2558.
   PubMed Web of Science ®Google Scholar
• Kessler R, Partridge MR, Miravitlles M, et al. Symptom variability in patients with severe COPD: a pan-European cross-sectional study. Eur Respir J. 2011;37(2):264–272.
   PubMed Web of Science ®Google Scholar
• Mocarski M, Zaiser E, Trundell D, et al. Evaluation of the psychometric properties of the Nighttime Symptoms of COPD Instrument. Int J Chron Obstruct Pulmon Dis. 2015;10:475–487.
   PubMed Web of Science ®Google Scholar
• Hareendran A, Make BJ, Zaiser E, et al. Evaluation of the psychometric properties of the Early Morning Symptoms of COPD Instrument (EMSCI). Int J Chron Obstruct Pulmon Dis. 2018;13:1633–1645.
   PubMed Web of Science ®Google Scholar
• Horner A, Burghuber OC, Hartl S, et al. Quality of life and limitations in daily life of stable COPD outpatients in a real-world setting in Austria – results from the CLARA project. Int J Chron Obstruct Pulmon Dis. 2020;15:1655–1663.
   PubMed Web of Science ®Google Scholar
• Celli B, Blasi F, Gaga M, et al. Perception of symptoms and quality of life – comparison of patients’ and physicians’ views in the COPD MIRROR study. Int J Chron Obstruct Pulmon Dis. 2017;12:2189–2196.
   PubMed Web of Science ®Google Scholar
• Jones PW, Beeh KM, Chapman KR, et al. Minimal clinically important differences in pharmacological trials. Am J Respir Crit Care Med. 2014;189(3):250–255.
   PubMed Web of Science ®Google Scholar
• O’Donnell DE, Laveneziana P. The clinical importance of dynamic lung hyperinflation in COPD. COPD. 2006;3(4):219–232.
   PubMedGoogle Scholar
• Rossi A, Aisanov Z, Avdeev S, et al. Mechanisms, assessment and therapeutic implications of lung hyperinflation in COPD. Respir Med. 2015;109(7):785–802.
   PubMed Web of Science ®Google Scholar
• Thomas M, Decramer M, O’Donnell DE. No room to breathe: the importance of lung hyperinflation in COPD. Prim Care Respir J. 2013;22(1):101–111.
   PubMedGoogle Scholar
• Watz H, Pitta F, Rochester CL, et al. An official European Respiratory Society statement on physical activity in COPD. Eur Respir J. 2014;44(6):1521–1537.
   PubMed Web of Science ®Google Scholar
• Esteban C, Quintana JM, Aburto M, et al. Impact of changes in physical activity on health-related quality of life among patients with COPD. Eur Respir J. 2010;36(2):292–300.
   PubMed Web of Science ®Google Scholar
• Garcia-Aymerich J, Lange P, Benet M, et al. Regular physical activity reduces hospital admission and mortality in chronic obstructive pulmonary disease: a population based cohort study. Thorax. 2006;61(9):772–778.
   PubMed Web of Science ®Google Scholar
• Donaldson GC, Seemungal TA, Bhowmik A, et al. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax. 2002;57(10):847–852.
   PubMed Web of Science ®Google Scholar
• Seemungal TA, Donaldson GC, Paul EA, et al. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1998;157(5):1418–1422.
   PubMed Web of Science ®Google Scholar
• Soler-Cataluña JJ, Martínez-García MA, Román Sánchez P, et al. Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease. Thorax. 2005;60(11):925–931.
   PubMed Web of Science ®Google Scholar
• Wise R, Chapman K, Scirica B, et al. Aclidinium bromide treatment stratified by exacerbation history: effects on exacerbations and major cardiovascular events in patients with COPD and high cardiovascular risk (ASCENT-COPD). Chest. 2019;156(4):A154–A156.
   Web of Science ®Google Scholar
• Wise RA, Chapman KR, Scirica BM, et al. Aclidinium bromide added to a long-acting B2 agonist ± inhaled corticosteroid: effects on exacerbations, lung function, and symptoms in patients with chronic obstructive pulmonary disease and cardiovascular risk factors (ASCENT-COPD). Am J Respir Crit Care Med. 2020;201:A2451.
   Google Scholar
• Singh D, Maleki-Yazdi MR, Tombs L, et al. Prevention of clinically important deteriorations in COPD with umeclidinium/vilanterol. Int J Chron Obstruct Pulmon Dis. 2016;11:1413–1424.
   PubMed Web of Science ®Google Scholar
• D’Urzo AD, Singh D, Donohue JF, et al. Aclidinium bromide in fixed-dose combination with formoterol fumarate in the management of COPD: an update on the evidence base. Ther Adv Respir Dis. 2019;13:1753466619850725.
   Web of Science ®Google Scholar
• Singh D, D’Urzo AD, Chuecos F, et al. Reduction in clinically important deterioration in chronic obstructive pulmonary disease with aclidinium/formoterol. Respir Res. 2017;18(1):106.
   PubMed Web of Science ®Google Scholar
• Maltais F, Bjermer L, Kerwin EM, et al. Efficacy of umeclidinium/vilanterol versus umeclidinium and salmeterol monotherapies in symptomatic patients with COPD not receiving inhaled corticosteroids: the EMAX randomised trial. Respir Res. 2019;20(1):238.
   PubMed Web of Science ®Google Scholar
• Dong Y-H, Lin H-H, Shau W-Y, et al. Comparative safety of inhaled medications in patients with chronic obstructive pulmonary disease: systematic review and mixed treatment comparison meta-analysis of randomised controlled trials. Thorax. 2013;68(1):48–56.
   PubMed Web of Science ®Google Scholar
• Celli B, Decramer M, Kesten S, et al. Mortality in the 4-year trial of tiotropium (UPLIFT) in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2009;180(10):948–955.
   PubMed Web of Science ®Google Scholar
• Baker JG. The selectivity of β-adrenoceptor antagonists at the human β1, β2 and β3 adrenoceptors. Br J Pharmacol. 2005;144(3):317–322.
   PubMed Web of Science ®Google Scholar
• Lipworth B, Wedzicha J, Devereux G, et al. Beta-blockers in COPD: time for reappraisal. Eur Respir J. 2016;48(3):880–888.
   PubMed Web of Science ®Google Scholar
• Lim KP, Loughrey S, Musk M, et al. Beta-blocker under-use in COPD patients. Int J Chron Obstruct Pulmon Dis. 2017;12:3041–3046.
   PubMed Web of Science ®Google Scholar
• Chapman KR, Wise RA, Scirica BM, et al. Aclidinium bromide treatment in patients receiving beta-blockers: effects on MACE, moderate/severe COPD exacerbations, and lung function in patients with moderate-to-very severe COPD and cardiovascular risk factors (ASCENT-COPD). Am J Respir Crit Care Med. 2019;199:A2443.
   Web of Science ®Google Scholar
• Bafadhel M, Peterson S, De Blas MA, et al. Predictors of exacerbation risk and response to budesonide in patients with chronic obstructive pulmonary disease: a post-hoc analysis of three randomised trials. Lancet Respir Med. 2018;6(2):117–126. Epub 2018 Jan 10.
   PubMed Web of Science ®Google Scholar
• Siddiqui SH, Guasconi A, Vestbo J, et al. Blood eosinophils: a biomarker of response to extrafine beclomethasone/formoterol in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2015;192(4):523–525.
   PubMed Web of Science ®Google Scholar
• Pascoe S, Locantore N, Dransfield MT, et al. Blood eosinophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: a secondary analysis of data from two parallel randomised controlled trials. Lancet Respir Med. 2015;3(6):435–442.
   PubMed Web of Science ®Google Scholar
• Brouwers MC, Kho ME, Browman GP, et al. AGREE II: advancing guideline development, reporting and evaluation in health care. Can Med Assoc J. 2010;182(18):E839–42.
   PubMed Web of Science ®Google Scholar
• Bourbeau J, Bhutani M, Hernandez P, et al. Canadian Thoracic Society Clinical Practice Guideline on pharmacotherapy in patients with COPD – 2019 update of evidence. Can J Respir Crit Care Sleep Med. 2019;3(4):210–232.
   Web of Science ®Google Scholar
• Singh D, D’Urzo AD, Donohue JF, et al. Weighing the evidence for pharmacological treatment interventions in mild COPD; a narrative perspective. Respir Res. 2019;20(1):141.
   PubMed Web of Science ®Google Scholar
• Lee JH, Cho MH, McDonald ML, et al. Phenotypic and genetic heterogeneity among subjects with mild airflow obstruction in COPDGene. Respir Med. 2014;108(10):1469–1480.
   PubMed Web of Science ®Google Scholar
• Zhou Y, Zhong NS, Li X, et al. Tiotropium in early-stage chronic obstructive pulmonary disease. N Engl J Med. 2017;377(10):923–935.
   PubMed Web of Science ®Google Scholar
• Singh D. One bronchodilator or two? Translating clinical trials into clinical practice. Respirology. 2020;25(4):352–353.
   PubMed Web of Science ®Google Scholar
• Roche N, Chapman KR, Vogelmeier CF, et al. Blood eosinophils and response to maintenance chronic obstructive pulmonary disease treatment. Data from the FLAME trial. Am J Respir Crit Care Med. 2017;195(9):1189–1197.
   PubMed Web of Science ®Google Scholar
• Singh D. Blood eosinophil counts in chronic obstructive pulmonary disease: a biomarker of inhaled corticosteroid effects. Tuberc Respir Dis. 2020;83(3):185–194.
   PubMed Web of Science ®Google Scholar
• White P, Thornton H, Pinnock H, et al. Overtreatment of COPD with Inhaled Corticosteroids - implications for safety and costs: cross-sectional observational study. PLoS One. 2013;8(10):e75221.
   PubMed Web of Science ®Google Scholar
• Price D, West D, Brusselle G, et al. Management of COPD in the UK primary-care setting: an analysis of real-life prescribing patterns. Int J Chron Obstruct Pulmon Dis. 2014;9:889–904.
   PubMed Web of Science ®Google Scholar
• Chalmers JD, Tebboth A, Gayle A, et al. Determinants of initial inhaled corticosteroid use in patients with GOLD A/B COPD: a retrospective study of UK general practice. NPJ Prim Care Respir Med. 2017;27(1):43.
   PubMed Web of Science ®Google Scholar
• Donohue JF, Worsley S, Zhu CQ, et al. Improvements in lung function with umeclidinium/vilanterol versus fluticasone propionate/salmeterol in patients with moderate-to-severe COPD and infrequent exacerbations. Respir Med. 2015;109(7):870–881.
   PubMed Web of Science ®Google Scholar
• Rodrigo GJ, Price D, Anzueto A, et al. LABA/LAMA combinations versus LAMA monotherapy or LABA/ICS in COPD: a systematic review and meta-analysis. Int J Chron Obstruct Pulmon Dis. 2017;12:907–922.
   PubMed Web of Science ®Google Scholar
• Wedzicha JA, Banerji D, Chapman KR, et al. Indacaterol–Glycopyrronium versus Salmeterol–Fluticasone for COPD. N Engl J Med. 2016;374(23):2222–2234.
   PubMed Web of Science ®Google Scholar
• Vogelmeier C, Paggiaro PL, Dorca J, et al. Efficacy and safety of aclidinium/formoterol versus salmeterol/fluticasone: a phase 3 COPD study. Eur Respir J. 2016;48(4):1030–1039.
   PubMed Web of Science ®Google Scholar
• Mahler DA, Ohar JA, Ferguson GT, et al. Pharmacotherapy for chronic obstructive pulmonary disease: molecules and delivery are equally important. Am J Respir Crit Care Med. 2020;202(10):1482.
   PubMed Web of Science ®Google Scholar